- Home
- ACAD vs KGS Comparison
ACAD vs KGS Comparison
Compare ACAD & KGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACAD | KGS |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 2000 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ACAD | KGS |
|---|---|---|
| Price | $23.65 | $50.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 6 |
| Target Price | $29.95 | ★ $46.80 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 04-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.88% |
| EPS Growth | ★ 467.57 | 93.10 |
| EPS | ★ 0.69 | 0.61 |
| Revenue | $726,437,000.00 | ★ $1,159,311,000.00 |
| Revenue This Year | $15.06 | $13.95 |
| Revenue Next Year | $11.34 | $8.78 |
| P/E Ratio | ★ $33.59 | $83.11 |
| Revenue Growth | ★ 40.45 | 36.33 |
| 52 Week Low | $14.08 | $29.25 |
| 52 Week High | $28.35 | $52.70 |
Technical Indicators
Market Signals| Indicator | ACAD | KGS |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 73.59 |
| Support Level | $21.51 | $49.00 |
| Resistance Level | $26.23 | $51.50 |
| Average True Range (ATR) | 0.86 | 1.78 |
| MACD | -0.05 | 0.27 |
| Stochastic Oscillator | 46.93 | 80.52 |
Price Performance
Historical ComparisonAbout ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About KGS Kodiak Gas Services Inc.
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.